Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25018206 | 1.00 | CA12 (0.34) | CA12CA1CA9FDPSKDM5A | |
| SCHEMBL10174210 | 0.95 | FDPS (0.33) | CA12CA1CA9FDPSKDM5A | |
| SCHEMBL842083 | 0.90 | KCNH2 (0.42) | CA12CA1CA9FDPSKDM5A | |
| SCHEMBL12437180 | 0.90 | CA12 (0.34) | CA12CA1CA9FDPSKDM5A | |
| SCHEMBL841648 | 0.83 | TSHR (0.32) | — | |
| SCHEMBL841608 | 0.83 | TSHR (0.32) | — | |
| SCHEMBL840929 | 0.83 | KCNH2 (0.47) | KDM5AKCNH2KDM4CDNM1 | |
| SCHEMBL3217467 | 0.83 | TSHR (0.31) | — | |
| SCHEMBL13267718 | 0.82 | DNM1 (0.40) | CA12CA1CA9FDPSKDM5A | |
| SCHEMBL13267614 | 0.82 | DNM1 (0.40) | CA12CA1CA9FDPSKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100775-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2021-04-08 | — | — | US | disclosed |
| US-20150258068-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2015-09-17 | — | — | US | disclosed |
| US-8916058-B2 | Fluorobetaine copolymer and fire fighting foam concentrates therefrom | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | CA12 1998/4885CA1 1631/4885CA9 2114/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | CA12 636/4885CA1 3091/4885CA9 236/4885 |
| US-20210100775-A1 | COMBINATION THERAPIES | DDIT3, MCL1, ERCC2 | CA12 3675/4885CA1 3898/4885CA9 3590/4885 |
| US-20150258068-A1 | COMBINATION THERAPIES | HDAC1, HDAC8, HDAC5 | CA12 3108/4885CA1 3264/4885CA9 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.